Use of intrinsic clearance for prediction of human hepatic clearance

Bibliography

• Chaturvedi PR, Decker CJ, Odinecs A. Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Curr Opin Chem Biol 2001;5(4):452-63
   PubMed Web of Science ®Google Scholar
• Korfmacher WA. Lead optimization strategies as part of a drug metabolism environment. Curr Opin Drug Discov Devel 2003;6(4):481-5
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997;283(1):46-58
   PubMed Web of Science ®Google Scholar
• Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999;27(11):1350-9
   PubMed Web of Science ®Google Scholar
• Shibata Y, Takahashi H, Ishii Y. A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab Dispos 2000;28(12):1518-23
   PubMed Web of Science ®Google Scholar
• Blanchard N, Richert L, Notter B, Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. Eur J Pharm Sci 2004;23(2):189-99
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM, Khojasteh SC, Halladay JS, Hop CE. On the prediction of hepatic clearance using the diluted plasma in metabolic stability assay. J Pharm Sci 2009;98(6):1922-7
   PubMed Web of Science ®Google Scholar
• Lu C, Li P, Gallegos R, Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 2006;34(9):1600-5
   PubMed Web of Science ®Google Scholar
• Lau YY, Sapidou E, Cui X, Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. Drug Metab Dispos 2002;30(12):1446-54
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Terashita S, Kagayama A, Sugiyama Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 2003;31(5):580-8
   PubMed Web of Science ®Google Scholar
• Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977;5(6):625-53
   PubMedGoogle Scholar
• Shibata Y, Takahashi H, Chiba M, Ishii Y. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab Dispos 2002;30(8):892-6
   PubMed Web of Science ®Google Scholar
• Stringer R, Nicklin PL, Houston JB. Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. Xenobiotica 2008;38(10):1313-29
   PubMed Web of Science ®Google Scholar
• Chao P, Maguire T, Novik E, Evaluation of a microfluidic-based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem Pharmacol 2009;78(6):625-32
   PubMed Web of Science ®Google Scholar
• Oh TI, Sung JH, Tatosian DA, Real-time fluorescence detection of multiple microscale cell culture analog devices in situ. Cytometry A 2007;71(10):857-65
   PubMedGoogle Scholar
• Viravaidya K, Sin A, Shuler ML. Development of a microscale cell culture analog to probe naphthalene toxicity. Biotechnol Prog 2004;20(1):316-23
   PubMed Web of Science ®Google Scholar
• Viravaidya K, Shuler ML. Incorporation of 3T3-L1 cells to mimic bioaccumulation in a microscale cell culture analog device for toxicity studies. Biotechnol Prog 2004;20(2):590-7
   PubMed Web of Science ®Google Scholar
• Sin A, Chin KC, Jamil MF, The design and fabrication of three-chamber microscale cell culture analog devices with integrated dissolved oxygen sensors. Biotechnol Prog 2004;20(1):338-45
   PubMed Web of Science ®Google Scholar
• Nebert DW, Adesnik M, Coon MJ, The P450 gene superfamily: recommended nomenclature. DNA 1987;6(1):1-11
   PubMedGoogle Scholar
• Guengerich FP. Uncommon P450-catalyzed reactions. Curr Drug Metab 2001;2(2):93-115
   PubMed Web of Science ®Google Scholar
• Gillette JR. Factors affecting drug metabolism. Ann NY Acad Sci 1971;179:43-66
   PubMed Web of Science ®Google Scholar
• Rowland M, Benet LZ, Graham GG. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1973;1(2):123-36
   PubMedGoogle Scholar
• Roberts MS, Rowland M. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J Pharmacokinet Biopharm 1986;14(3):227-60
   PubMedGoogle Scholar
• Roberts MS, Rowland M. A dispersion model of hepatic elimination: 2. Steady-state considerations–influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity. J Pharmacokinet Biopharm 1986;14(3):261-88
   PubMedGoogle Scholar
• Griffin SJ, Houston JB. Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance. Drug Metab Dispos 2004;32(5):552-8
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. Some features of the kinetics and equilibrium of drug binding to plasma proteins. Expert Opin Drug Metab Toxicol 2008;4(12):1479-98
   PubMed Web of Science ®Google Scholar
• Chao P, Barminko J, Novik E, Prediction of human hepatic clearance using an in vitro plated hepatocyte clearance model. Drug Metab Lett 2009. In press
   PubMedGoogle Scholar
• Nishikawa M, Kojima N, Komori K, Enhanced maintenance and functions of rat hepatocytes induced by combination of on-site oxygenation and coculture with fibroblasts. J Biotechnol 2008;133(2):253-60
   PubMed Web of Science ®Google Scholar
• Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. Nat Biotechnol 2008;26(1):120-6
   PubMed Web of Science ®Google Scholar
• Shackman JG, Dahlgren GM, Peters JL, Kennedy RT. Perfusion and chemical monitoring of living cells on a microfluidic chip. Lab Chip 2005;5(1):56-63
   PubMed Web of Science ®Google Scholar
• Kimura H, Yamamoto T, Sakai H, An integrated microfluidic system for long-term perfusion culture and on-line monitoring of intestinal tissue models. Lab Chip 2008;8(5):741-6
   PubMed Web of Science ®Google Scholar
• Toh YC, Lim TC, Tai D, A microfluidic 3D hepatocyte chip for drug toxicity testing. Lab Chip 2009;9(14):2026-35
   PubMed Web of Science ®Google Scholar
• Leclerc E, David B, Griscom L, Study of osteoblastic cells in a microfluidic environment. Biomaterials 2006;27(4):586-95
   PubMed Web of Science ®Google Scholar
• Tatosian DA, Shuler ML. A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers. Biotechnol Bioeng 2009;103(1):187-98
   PubMed Web of Science ®Google Scholar
• Kim M, Yeon J, Park J-K. A microfluidic platform for 3-dimensional cell culture and cell-based assays. Biomed Microdevices 2007;9(1):25-34
   PubMed Web of Science ®Google Scholar
• Park J, Berthiaume F, Toner M, Microfabricated grooved substrates as platforms for bioartificial liver reactors. Biotechnol Bioeng 2005;90(5):632-44
   PubMed Web of Science ®Google Scholar
• Sivaraman A, Leach JK, Townsend S, A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr Drug Metab 2005;6(6):569-91
   PubMed Web of Science ®Google Scholar
• El-Ali J, Sorger PK, Jensen KF. Cells on chips. Nature 2006;442(7101):403-11
   PubMed Web of Science ®Google Scholar
• Toepke MW, Beebe DJ. PDMS absorption of small molecules and consequences in microfluidic applications. Lab Chip 2006;6(12):1484-6
   PubMed Web of Science ®Google Scholar
• Schmitmeier S, Langsch A, Jasmund I, Bader A. Development and characterization of a small-scale bioreactor based on a bioartificial hepatic culture model for predictive pharmacological in vitro screenings. Biotechnol Bioeng 2006;95(6):1198-206
   PubMed Web of Science ®Google Scholar
• Zeilinger K, Sauer IM, Pless G, Three-dimensional co-culture of primary human liver cells in bioreactors for in vitro drug studies: effects of the initial cell quality on the long-term maintenance of hepatocyte-specific functions. Altern Lab Anim 2002;30(5):525-38
   PubMed Web of Science ®Google Scholar
• Gebhardt R, Lippert C, Schneider A, Doehmer J. Improved determination of drug metabolism by perifusion of recombinant V79 cells carrying human CYP3A4. Toxicol In Vitro 1999;13(4-5):639-43
   PubMed Web of Science ®Google Scholar
• Schumacher K, Khong YM, Chang S, Perfusion culture improves the maintenance of cultured liver tissue slices. Tissue Eng 2007;13(1):197-205
   PubMedGoogle Scholar
• Kane BJ, Zinner MJ, Yarmush ML, Toner M. Liver-specific functional studies in a microfluidic array of primary mammalian hepatocytes. Anal Chem 2006;78(13):4291-8
   PubMed Web of Science ®Google Scholar
• Gebhardt R, Wegner H, Alber J. Perifusion of co-cultured hepatocytes: optimization of studies on drug metabolism and cytotoxicity in vitro. Cell Biol Toxicol 1996;12(2):57-68
   PubMed Web of Science ®Google Scholar
• Bader A, Fruhauf N, Zech K, Development of a small-scale bioreactor for drug metabolism studies maintaining hepatospecific functions. Xenobiotica 1998;28(9):815-25
   PubMed Web of Science ®Google Scholar
• Langsch A, Bader A. Longterm stability of phase I and phase II enzymes of porcine liver cells in flat membrane bioreactors. Biotechnol Bioeng 2001;76(2):115-25
   PubMed Web of Science ®Google Scholar
• Iwahori T, Matsuura T, Maehashi H, CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. Hepatology 2003;37(3):665-73
   PubMed Web of Science ®Google Scholar
• Lau YY, Wu CY, Okochi H, Benet LZ. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther 2004;308(3):1040-5
   PubMed Web of Science ®Google Scholar
• Brown HS, Griffin M, Houston JB. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 2007;35(2):293-301
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. Determination of drug binding to plasma proteins using competitive equilibrium binding to dextran-coated charcoal. J Pharmacokinet Pharmacodyn 2006;33(5):595-608
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. On the calculation of the concentration dependence of drug binding to plasma proteins with multiple binding sites of different affinities: determination of the possible variation of the unbound drug fraction and calculation of the number of binding sites of the protein. J Pharm Sci 2007;96(2):249-57
   PubMed Web of Science ®Google Scholar
• Li C, Nair L, Liu T, Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors. Biochem Pharmacol 2008;75(5):1186-97
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Terashita S, Kimura S, Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 2001;29(10):1316-24
   PubMed Web of Science ®Google Scholar
• Ito K, Houston JB. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res 2004;21(5):785-92
   PubMed Web of Science ®Google Scholar
• Yang J, Jamei M, Yeo KR, Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos 2007;35(3):501-2
   PubMed Web of Science ®Google Scholar
• Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's. The pharmacological basis of therapeutics. 11th edition. New York: McGRAW-HILL, Medical Publishing Division; 2006
   Google Scholar
• Li C, Liu T, Cui X, Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans. J Biomol Screen 2007;12(8):1084-91
   PubMed Web of Science ®Google Scholar